trans-4-dimethylaminocrotonic Acidum hydrochloridum CAS 848133-35-7 Puritas >98.0% (HPLC) Afatinib Dimaleate Intermedia

Description:

trans-4-Dimethylaminocrotonic Acidum hydrochloridum

CAS: 848133-35-7

Puritas: >98.0% (HPLC)

Aspectus: Alba ad fere alba pulveris

Afatinib Dimaleate (CAS: 850140-73-7)

Contactus: Dr

Mobile/Wechat/Whatsapp: +86-15026746401

E-Mail: alvin@ruifuchem.com

Mitte ad nos inscriptio

Product Detail

Product Tags

Descriptio:

Ruifu Chemical Supple intermedia de Afatinib
Afatinib CAS 439081-18-2
Afatinib Dimaleate CAS 850140-73-7
(S)-(+)-3-Hydroxytetrahydrofuran CAS 86087-23-2
acetaldehyda Diethyl acetalis CAS 3616-56-6
trans-4-dimethylaminocrotonic Acidum hydrochloridum CAS 848133-35-75
Diethylphosphonoaceticum acidum CAS 3095-95-2
7-Fluoro-6-Nitroquinazolin-4(1H)-one CAS 162012-69-3
7-Chloro-6-Nitro-4-Hydroxyquinazoline CAS 53449-14-2
N-(3-Chloro-4-Fluorophenyl)-7-Fluoro-6-Nitroquinazolin-4-Amine CAS 162012-67-1
(S)-N4-(3-Chloro-4-Fluorophenyl) -7-((Tetrahydrofuran-3-yl)oxy)quinazoline-4,6-DiamineCAS 314771-76-1
(S)-N-(3-Chloro-4-Fluorophenyl)-6-Nitro-7-((Tetrahydrofuran-3-yl)oxy)quinazolin-4-AmineCAS 314771-88-5

Chemical Properties:

Nomen chemicum	trans-4-Dimethylaminocrotonic Acidum hydrochloridum
Synonyma	trans 4-Dimethylaminocrotonic Acid HCl;(E) -4-(Dimethylamino) -2-Butenoicum Acidum hydrochloridum;(E) -4-Dimethylaminocrotonic Acidum hydrochloridum;(2E)-4-(Dimethylamino)sed-2-Enoicum Acidum hydrochloridum;Afatinib int-2
CAS Number	848133-35-7
Stock Status	In Stock, Commercial Scale
Formulae hypotheticae	C6H12ClNO2
M. Pondus	165.62
Sensibilitas	Hygroscopic.umorem Sensitivum
Liquescens punctum	160.0 ad 164.0℃
Solubilitas	DMSO (paulo), Methanol (paulo), aqua (paulo)
COA & MSDS	Praesto
Origin	Shanghai, China
Brand	Ruifu Chemical

Specifications:

Item	Specifications
Aspectus	Alba ad fere album pulveris
Puritas / Analysis Methodus	>98.0% (HPLC)
Puritas / Analysis Methodus	>98.0% (NMR)
Humor (KF)	<0.50%
Residere in Ignition	<0.20%
una immunditia	<0.50%
Metalla gravia (ut Pb)	<20ppm
Infrared Imaginis	Conformat ut Structure
1 H NMR Spectrum	Proton NMR Spectrum
Test Standard	Enterprise Standard
Consuetudinem	Medium Afatinib, Afatinib Dimaleate

Sarcina & Repono:

Sarcina:Utrem, aluminium foil, sacculum, 25kg/cardboard Drum, vel secundum exigentiam emptoris.

Repono Condition:Repone in vasis signatis in loco frigido et sicco;A luce et humore protege.

Naviportans:Libera ad mundum ab aere, per FedEx / DHL Express.Ieiunium et certas traditiones provide.

Puritas chromatographica:

Instrument: Agilent 1200 HPLC HPLC chromatographum DAD detector.
Columna: Agilent XDB-C18,250*4.6mm, 5μm
Mobile tempus: B: 1.95g sodium octanum sulfonatum + 8ml acidum phosphoricum + 5ml triethylamine + 500ml aquae
C: acetonitrile
Praeparatio periodi mixti mobilis: sume solutionem 400ml B et 100ml acetonitrilem, permisce et aequaliter, et liquorem in una periodo sentinam.
Fluunt rate: 0.5ml/min54bar
Columna temperatus: 25℃
Necem: 210nm
Sample solutio: periodus mobilis adhibita est specimen solvendo solidumque: 0.0040g/2ml, magnitudine exempli 2.0μl.

commoda:

FAQ:

Applicatio:

trans-4-dimethylaminocrotonicum acidum hydrochloridum (CAS: 848133-35-7) adhibitum gerens in praeparatione kinasi tyrosinae inhibito agentium antitumore.trans-4-dimethylaminocrotonic Acidum hydrochloridum ut medium inter Afatinib (CAS: 439081-18-2), Afatinib Dimaleate (CAS: 850140-73-7), Neratinib (CAS: 698387-09-6).Afatinib est medicamentum approbatum ad carcinoma pulmonis non parvae cellae curationis (NSCLC), a Boehringer Ingelheim evoluta.Agit angiokinase inhibitor.Sicut Lapatinib et Neratinib, Afatinib est tyrosinus kinasus inhibitor (TKI), qui etiam irrevocabiliter vetat factorem 2 (Her2) et factor incrementi epidermalis receptor 2 (Her2) et kinases receptae incrementi epidermalis.Afatinib non solum active contra EGFRmutationes primae generationis iaculis TKIs likeerlotinib vel gefitinib, sed etiam contra illas therapias normas non sensitivas.Propter additam actionem contra Her2, investigatur pro carcinomate pectoris necnon aliis EGFR et Her2 carcinomata agitata.Neratinib a US Wyeth evolvitur, factor incrementi epidermalis irreversibilis inhibitor (EGFR) est.Est multiplex scopus punctum inhibitores kinasi minoris moleculae tyrosinae inhibitores HER 2 et HER1 post Lapatinib, et est irreversibilis ErbB receptor inhibitoris tyrosini kinasi.Neratinib selective inhibere potuit HER-1 et HER-2 familiae EGFR (IC50 erat 92 nmol/L et 59 nmol/L, respective).Fusce Investigationes demonstraverunt Neratinib significans effectus medicinales exerceri in cancer cellulis non parvis, cancer coli, et cancer pectus.PhaseⅡclinicum iudicium significavit Neratinib ostendit bonam efficaciam et tolerantiam in HER-2 positivos aegros cum carcinomate pectoris provectos, qui curatione Trastuzumab accepti vel non sunt.Phase Ⅲ cancer pretium orci integrum mense Septembri MMXIV erat iudicium.